HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 12/28/2012 -- Procter & Gamble Company’s (NYSE:PG) license agreement with Inter Parfums (NASDAQ:IPAR) terminates on April 3rd, but the latter has entered into a ten-year exclusive worldwide fragrance license to create, manufacture, and distribute perfumes and fragrance-related products under the Alfred Dunhill Limited brand in an accord that begins on the same date. The latter will assume production and distribution of the existing Alfred Dunhill fragrance collections with sales of current fragrances planned for Spring, and a new men’s scent is being readied for 2014.
Should PG Smartly Rally from Here : Check Here
Hewlett-Packard Company (NYSE:HPQ) and Lenovo (LNVGY) should experience better shipment performance than Acer and Asustek in January because of strong demand in China, says DigiTimes. Taiwan-based supply chain makers report that the majority of notebook vendors are expected to suffer from slumping performance in the first quarter.
Is HPQ A Secure Investment? Watch Out An Over View of BBY Here
Pfizer (NYSE:PFE) and Bristol-Myers Squibb Company said that the Ministry of Health, Labor and Welfare of Japan has cleared Eliquis for the prevention of ischemic stroke and systemic embolism in patients suffering from nonvalvular atrial fibrillation. The drug is a novel anticoagulant that has shown risk reductions compared to warfarin in three important outcomes of stroke, major bleeding and all-cause death. Eliquis is an oral direct Factor Xa inhibitor, part of a novel therapeutic class. This marks the third approval for the drug for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation following approvals in the European Union and Canada.
Should Investor Book Profit and Exit From PFE: Need Instant Reply Check Here
InterMune (NASDAQ:ITMN) and three members of an independent advisory panel say that they had as much as a day’s notice before the rejection, an admission that is now linked with an insider trading probe of SAC Capital Advisors. On the day before the official announcement, InterMune shares dropped 5.4 percent on the day, during which the panel members know that the drug was doomed. However, others at the firm and at the FDA were also aware of the rejection, but there is no evidence the 11 panelists did anything inproper.
Ready To Get Instant Analysis Report From Here: Just Check Now
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)